Today: 9 April 2026
Subscribe
Browse Category

NYSE:GSK 11 November 2025 - 17 December 2025

GSK Stock News Today (Dec. 17, 2025): FDA Approves Twice‑Yearly Asthma Drug Exdensur as Analysts Reassess GSK plc’s 2026 Outlook

GSK Stock News Today (Dec. 17, 2025): FDA Approves Twice‑Yearly Asthma Drug Exdensur as Analysts Reassess GSK plc’s 2026 Outlook

The FDA approved GSK’s Exdensur (depemokimab-ulaa) on Dec. 17 as a twice-yearly add-on treatment for severe eosinophilic asthma in patients 12 and older. Phase III trials showed up to 58% fewer annual asthma exacerbations versus placebo. The FDA declined approval for a second indication, chronic rhinosinusitis with nasal polyps. GSK faces a leadership change Jan. 1, 2026.
17 December 2025
··
GSK plc Stock News & Forecasts (Dec. 15, 2025): FDA Catalyst for Depemokimab, EU Backs Nucala and Arexvy, Analysts Map the Path Ahead

GSK plc Stock News & Forecasts (Dec. 15, 2025): FDA Catalyst for Depemokimab, EU Backs Nucala and Arexvy, Analysts Map the Path Ahead

GSK faces a key FDA decision on depemokimab for severe asthma and nasal polyps on Dec. 16, following recent EU regulatory backing for the drug and other respiratory products. GSK ADRs last traded at $48.81, while London shares opened at 1,816.50p. Analysts are watching for potential shifts in revenue forecasts and valuation as regulatory outcomes approach.
15 December 2025
··
GSK Stock News Today (Dec. 12, 2025): Arexvy EU Expansion, Blujepa FDA Approval, Analyst Forecasts and What’s Next

GSK Stock News Today (Dec. 12, 2025): Arexvy EU Expansion, Blujepa FDA Approval, Analyst Forecasts and What’s Next

GSK shares traded near $48.88 Friday as the company reported key regulatory wins. The EMA’s CHMP backed expanding Arexvy’s RSV vaccine to all adults 18+ in Europe, with a final decision expected in February. The FDA also approved Blujepa (gepotidacin) for gonorrhea, marking the first new antibiotic class for the infection in decades. Analyst consensus sees Arexvy sales rising to £1.17 billion by 2031.
12 December 2025
··
GSK Stock on 10 December 2025: FDA Orphan-Drug Win, New Cancer Deal and What It Means for Investors

GSK Stock on 10 December 2025: FDA Orphan-Drug Win, New Cancer Deal and What It Means for Investors

The US FDA granted Orphan Drug Designation to GSK’s experimental lung cancer therapy risvutatug rezetecan on December 10. GSK shares traded near 1,780 pence in London, up about 29% over 12 months. The drug targets small-cell lung cancer and has shown durable responses in early trials. GSK’s US ADR closed at $47.27, near its 52-week high.
10 December 2025
···
GSK Stock Near 52-Week Highs: Upgraded 2025 Guidance, Buybacks and Zantac Relief Fuel Re‑Rating

GSK Stock Near 52-Week Highs: Upgraded 2025 Guidance, Buybacks and Zantac Relief Fuel Re‑Rating

GSK shares traded near 52-week highs on December 9, 2025, with London shares at £18.05 and NYSE ADRs at $48.5, both up over 30% year-on-year. The stock surged after a Q3 earnings beat and upgraded 2025 guidance, driven by strong HIV and oncology drug sales. GSK now expects full-year sales growth of 6–7% and core EPS growth of 10–12%.
9 December 2025
···
GSK plc Stock in December 2025: Buybacks, New CEO and Strong Q3 Results Drive a 40% Rally

GSK plc Stock in December 2025: Buybacks, New CEO and Strong Q3 Results Drive a 40% Rally

GSK shares traded near multi-year highs on 4 December, closing at 1,826–1,837p in London and $48.57 in New York, up over 40% year-to-date. The company repurchased more than 11.5 million shares since late September as part of a £2 billion buyback. New executive share options were granted on 5 December. Market cap stands at about £73 billion in London and just under $100 billion in New York.
5 December 2025
··
GSK plc Stock Today: Q3 Beat, Blenrep Comeback and a New CEO – Full Investor Update for 2 December 2025

GSK plc Stock Today: Q3 Beat, Blenrep Comeback and a New CEO – Full Investor Update for 2 December 2025

GSK closed near 1,783p in London on 2 December 2025, just below its 52-week high, after strong Q2 and Q3 results lifted shares nearly 40% over 12 months. Q3 sales rose 8% at constant exchange to £8.5 billion, with oncology up 39% and core EPS up 14%. The ADR ended at $47.19 in New York. Analyst focus remains on the company’s growth pipeline and 2031 revenue targets.
2 December 2025
····
GSK Stock on 1 December 2025: Big 2025 Rally, Blenrep’s Comeback and a New CEO – What Investors Need to Know Now

GSK Stock on 1 December 2025: Big 2025 Rally, Blenrep’s Comeback and a New CEO – What Investors Need to Know Now

GSK shares closed at $47.9 on November 28, just below a 52-week high, after a year-to-date gain of about 30–40%. The company beat earnings expectations in Q2 and Q3, raised full-year guidance, and saw its cancer drug Blenrep re-approved in major markets. CEO Emma Walmsley will step down December 31, with Luke Miels to take over January 1. Most analysts rate the stock a “Hold” despite recent outperformance.
1 December 2025
··
GSK (GSK) news today — Nov 11, 2025: New AN2 TB collaboration, buyback activity filed, shares test 12‑month high

GSK Share Price Today, 20 November 2025: LON:GSK Edges Higher as Jefferies Lifts Target and Oncology Deal Builds Momentum

GSK shares closed up 0.23% at 1,776p in London on Thursday, trading between 1,772p and 1,790p on light volume. Jefferies raised its target price to 2,100p and reiterated a “Buy” rating. Recent R&D announcements and a new oncology collaboration with LTZ Therapeutics continued to influence sentiment. Over the past year, GSK shares have gained about 36%.
20 November 2025
··
1 2

Stock Market Today

  • QuidelOrtho (QDEL) Shares Slide 23% in a Month Amid Valuation Debate
    April 8, 2026, 9:37 PM EDT. QuidelOrtho (QDEL) shares slipped 22.86% over the past month to $15.32, despite a 2.27% gain on the latest trading day. The stock's 1-year total shareholder return tallies 46.90%, showing past momentum is fading. Analysts flag a sharp valuation gap: market price trails the $34.67 fair value estimate by over 80%, spotlighting risks in execution and reimbursement trends. Expansion into global markets like Latin America and Asia Pacific offers growth potential, underpinned by demand for early detection and immunoassay technologies. But COVID testing normalization and product discontinuations weigh on revenue diversity and margins. Investors should weigh these mixed signals carefully and consider broadening healthcare AI exposure rather than concentrating on one stock story.

Latest article

Why IREN Stock Is Back in Focus as AI Ambitions Meet Funding Fears

Why IREN Stock Is Back in Focus as AI Ambitions Meet Funding Fears

8 April 2026
IREN shares rose 1.8% to $35.74 Wednesday as investors assessed its $6 billion share program and shift from bitcoin mining to AI cloud services. The company’s revenue fell to $184.7 million last quarter, with a net loss of $155.4 million. IREN recently announced a five-year, $9.7 billion AI cloud deal with Microsoft. Options trading volume hit 103,000 contracts Tuesday, with sentiment described as mixed.
Amazon Stock Could Jump 50% as Wall Street Reconsiders Its $200 Billion AI Bet

Amazon Stock Could Jump 50% as Wall Street Reconsiders Its $200 Billion AI Bet

8 April 2026
Amazon closed at $213.77 Tuesday, with BNP Paribas maintaining a $320 price target, citing strong AI demand despite Amazon’s planned $200 billion capex for 2026. The company’s February forecast of higher spending sent shares down 11.5% after hours, even as AWS revenue rose 24% to $35.6 billion in the December quarter. Alphabet and Microsoft are also ramping up AI infrastructure spending.
Sensex Soars 2,946 Points, Nifty Near 24,000 After Iran Ceasefire and RBI Pause

Sensex Soars 2,946 Points, Nifty Near 24,000 After Iran Ceasefire and RBI Pause

8 April 2026
The Sensex surged 2,946 points to 77,562.90 on Wednesday, its best day in five years, as a U.S.-Iran ceasefire and steady RBI rates pushed Indian markets higher. Brent crude fell 14.4% to $93.49 a barrel, easing pressure on the rupee, which rose 0.5% to 92.58 per dollar. All 16 major sectors gained, led by financials and auto stocks. The RBI kept its repo rate at 5.25% and forecast slower growth ahead.
Netflix Stock Draws Fresh Institutional Buying Ahead of Earnings After Goldman Upgrade

Netflix Stock Draws Fresh Institutional Buying Ahead of Earnings After Goldman Upgrade

8 April 2026
Stock Yards Bank & Trust Co. increased its Netflix stake by 1,141.9% to 29,074 shares in Q4, while Ethos Capital Management disclosed a new 19,610-share position worth $1.84 million. The moves come ahead of Netflix’s April 16 earnings report and follow a Goldman Sachs upgrade to Buy with a $120 target. Insiders Reed Hastings and Greg Peters sold shares earlier this year under preset trading plans. Netflix last traded at $98.82.
Alphabet Stock (GOOG, GOOGL) Faces Split Fund Bets Ahead of Earnings After Fresh 13F Reports

Alphabet Stock (GOOG, GOOGL) Faces Split Fund Bets Ahead of Earnings After Fresh 13F Reports

8 April 2026
Zevenbergen Capital increased its Alphabet Class A share holdings by 27.4% in Q4, while Lombard Odier and Empirical Wealth Management reduced their Class C positions, according to April 7 filings. Alphabet will report first-quarter results on April 29. GOOG and GOOGL traded near $304 before Wednesday’s U.S. open. The filings reflect holdings as of December 31 and may not show current positions.
Go toTop